Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.

ABSTRACT:

Background

Although TP53 and RB1 co-alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co-alteration are lacking. We performed a pan-cancer analysis to characterize the biology of TP53/RB1 co-alterations and identify therapeutic strategies.

Methods

We analyzed mutation data and copy number variation (CNV) data from 42 371 pan-cancer samples across 26 cancer types from the cBioPortal database. Among them, 2417 tumors with TP53/RB1 co-alterations were used for further analysis. We characterized their epidemiology and molecular biology. Therapeutic vulnerabilities of co-altered tumors were examined using Cancer Cell Line Encyclopedia drug screening datasets.

Results

TP53/RB1 co-alterations occurred in 5.

SUBMITTER: Li X 

PROVIDER: S-EPMC12820914 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature